Clinical trials: Hypopigmented Skin
Vitiligo, Non-Segmental Vitiligo (NSV)
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo.
- Trial name
- NCT07533019
- Testing
- LY4005130
- Where
- 35 sites in United States, Belgium and 3 more
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Chronic Heart Failure, Old Myocardial Infarction
Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration
The purpose of this study is to determine the safety and effectiveness of intracoronary infusion of autologous cardiac stem cells in patients with ischemic cardiomyopathy.
- Trial name
- JOKER (NCT03351400)
- Testing
- Stem cells administered to participants
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Sakakibara Heart Institute
Vitiligo, Repigmentation
Topical Bimatoprost Solution 0.03%in Stable Vitiligo
Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives…
- Trial name
- NCT01202513
- Testing
- Bimatoprost 0.03% topical ophthalmic solution
- Volunteers
- 20 people
- Sponsor
- Gian Sagar Medical College and Hospital
Hermanski-Pudlak Syndrome, Colitis
Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
This study will determine if medical treatment of colitis (inflammation of the colon resulting in loose bowel movements, rectal bleeding, and belly pain) that is used for other colitis conditions, such as Crohn's disease and…
- Conditions
- Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes
- Trial name
- NCT00514982
- Testing
- Mesalamine, Infliximab, Corticosteroids
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vitiligo
Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study
Vitiligo is an acquired pigmentary disorder on skin and/or mucosae, which is characterized by death of melanocytes (MCs), affecting 0.5%-2% of the population worldwide (1).
- Trial name
- NCT06261086
- Testing
- evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Vitiligo, Piebaldism
Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
The purpose of this study is to assess the efficacy of autologous epidermal cells suspension grafting using a newly developed device named VITICELL® compared to placebo.
- Trial name
- NCT02156427
- Testing
- VITICELL
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Laboratoires Genévrier
Myelofibrosis, Gaucher Disease
Clinical and Pathophysiological Investigations Into Erdheim Chester Disease
Background: Erdheim Chester Disease (ECD) is a very rare disease in which abnormal white blood cells start growing and affect the bones, kidneys, skin, and brain.
- Conditions
- Myelofibrosis, Gaucher Disease, Pulmonary Fibrosis, Hermansky-Pudlak Syndrome (HPS)
- Trial name
- NCT01417520
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Leukemia
A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
This is a Phase I-II study evaluating the toxicity and efficacy of imatinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy in relapsed and refractory AML.
- Trial name
- NCT01126814
- Testing
- Imatinib (Gleevec)
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Hermansky Pudlak Syndrome
A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Hermansky-Pudlak Syndrome (HPS) is a rare genetic disease that is associated with oculocutaneous albinism, bleeding, granulomatous colitis, and pulmonary fibrosis in some subtypes, including HPS-1, HPS-2, and HPS-4.
- Trial name
- NCT02368340
- Testing
- Pulmonary function test, Chest CT, Sample collection
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Vanderbilt University
Upper Cross Syndrome
Fascial Release on Upper Cross Syndrome.
This study will be a randomized controlled trial conducted to investigate the effect of release of upper track of deep front fascial line on patients with Upper Cross Syndrome.A sample size of 40 will be randomly allocated to two…
- Trial name
- NCT06004076
- Testing
- Release of upper track of deep front fascial line, Corrective exercises for upper crossed syndrome
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Vitiligo, Hearing Loss
Audiological Disturbances in Vitiligo
The purpose of this study is to determine wether vitiligo patients have more audiological abmnormalities, than the healthy population.
- Trial name
- NCT00484224
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Burn Scar, Hypertrophic Scar
Characterization of Dyschromic Hypertrophic Scar
Currently, there are limited prevention or treatments available for dyschromia in burn hypertrophic scars (HTSs). The limited available techniques involve transferring melanocytes from unaffected areas to the scar to adjust…
- Conditions
- Burn Scar, Hypertrophic Scar, Hyperpigmentation, Hypopigmented Scar
- Trial name
- NCT04619589
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medstar Health Research Institute
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Vitiligo
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.
- Trial name
- GB (NCT01006421)
- Testing
- GINGKO BILOBA
- Where
- Saudi Arabia
- Volunteers
- 160 people
- Sponsor
- King Saud University
Psoriasis, Cutaneous T Cell Lymphoma
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or…
- Conditions
- Psoriasis, Cutaneous T Cell Lymphoma, Lymphoproliferative Disorders, Eczema
- Trial name
- BioUV2017 (NCT03340155)
- Testing
- Photo(chemo)therapy
- Where
- Austria
- Volunteers
- 240 people
- Sponsor
- Medical University of Graz